Sumitomo Pharma Co Ltd
TSE:4506
Sumitomo Pharma Co Ltd
Other Equity
Sumitomo Pharma Co Ltd
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sumitomo Pharma Co Ltd
TSE:4506
|
Other Equity
¥102.8B
|
CAGR 3-Years
87%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
5%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Other Equity
¥2.7T
|
CAGR 3-Years
70%
|
CAGR 5-Years
67%
|
CAGR 10-Years
18%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Other Equity
¥263.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
26%
|
CAGR 10-Years
5%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Other Equity
¥336.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Other Equity
¥11.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
21%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Other Equity
¥521.6B
|
CAGR 3-Years
28%
|
CAGR 5-Years
37%
|
CAGR 10-Years
11%
|
|
Sumitomo Pharma Co Ltd
Glance View
In the bustling world of pharmaceuticals, Sumitomo Pharma Co. Ltd. stands as a testament to innovation and resilience. Emerging from its roots in Sumitomo Dainippon Pharma, this Japanese giant has been weaving a complex tapestry of cutting-edge medical advancements and strategic mergers for decades. At its core, Sumitomo Pharma is fueled by an unwavering commitment to research and development, driving its efforts in therapeutic areas such as psychiatry, neurology, and oncology. These focal points aren't mere business segments but vital lifelines that the company seeks to improve with its products. Their success heavily relies on their ability to translate research into actionable, marketable treatments; it's a dance between science and commerce, with the rhythm dictated by patient needs and market demands. Sumitomo Pharma's financial engine is powered not just by their innovative drug pipeline but also through savvy global partnerships and strategic acquisitions. By expanding its footprint across North America, Europe, and Asia, the company meticulously builds a global distribution network that ensures its products reach the hands of physicians and patients worldwide. This extensive reach allows Sumitomo Pharma to tap into diverse markets, fueling both sales and brand recognition. Moreover, through its alliances with biotech firms and academic institutions, the company enhances its research capabilities, fostering a cycle of innovation that feeds back into its financial growth. In essence, Sumitomo Pharma doesn't just participate in the pharmaceutical industry; it actively shapes it, both through its dedication to breakthrough therapies and its strategic navigation of complex global markets.
See Also
What is Sumitomo Pharma Co Ltd's Other Equity?
Other Equity
102.8B
JPY
Based on the financial report for Dec 31, 2024, Sumitomo Pharma Co Ltd's Other Equity amounts to 102.8B JPY.
What is Sumitomo Pharma Co Ltd's Other Equity growth rate?
Other Equity CAGR 10Y
5%
Over the last year, the Other Equity growth was 20%. The average annual Other Equity growth rates for Sumitomo Pharma Co Ltd have been 87% over the past three years , and 5% over the past ten years .
You don't have any saved screeners yet